Financials data is unavailable for this security.
View more
Year on year Arrowhead Pharmaceuticals Inc 's net income fell 16.59% from a loss of 176.06m to a larger loss of 205.28m despite relatively flat revenues.
| Gross margin | -- |
|---|---|
| Net profit margin | -2,785.85% |
| Operating margin | -2,785.05% |
| Return on assets | -65.18% |
|---|---|
| Return on equity | -154.92% |
| Return on investment | -73.62% |
More ▼
Cash flow in USDView more
In 2023, Arrowhead Pharmaceuticals Inc did not generate a significant amount of cash. Cash Flow from Financing totalled 253.05m or 105.12% of revenues. In addition the company used 153.89m for operations while cash used for investing totalled 96.16m.
| Cash flow per share | -4.59 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 2.66 |
|---|---|
| Tangible book value per share | 2.59 |
More ▼
Balance sheet in USDView more
| Current ratio | 4.65 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
Growth rates in USD
Year on year, growth in earnings per share excluding extraordinary items dropped -15.15%.
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -172.13 |
